Human Longevity in 2026: What the Latest Science Really Says About Living Longer

Direct answer: As of 2026, no drug, supplement, or therapy has been proven in a rigorous human trial to extend maximum human lifespan. What the science does show is far more useful: aging is a biological process with measurable, modifiable drivers — the "hallmarks of aging" — and a growing set of interventions can slow or partially reverse those drivers in laboratory animals, with a handful now in early human trials targeting healthspan (years lived in good health) rather than raw lifespan. The strongest human evidence still sits with the unglamorous basics: regular exercise, good sleep, not smoking, and a sensible diet. The frontier — senolytics, rapamycin, GLP-1 drugs, NAD+ precursors, and cellular reprogramming — is genuinely promising but largely unproven in people. This article separates what is established from what is hopeful.

Educational content only — not medical advice. See the disclaimer at the end.

Key Takeaways

• Aging is now framed as a set of 12 interconnected biological "hallmarks" (López-Otín et al., Cell, 2023). The "geroscience hypothesis" holds that targeting these shared drivers could delay multiple age-related diseases at once.
• The goal of serious longevity science is healthspan, not immortality. Compressing the years of late-life disease is the realistic, evidence-backed target.
• The most proven longevity interventions are behavioral, not pharmaceutical: exercise, sleep, not smoking, and dietary quality have decades of robust human outcome data.
• Caloric restriction modestly slowed one measure of biological aging in the CALERIE human trial (~2–3% on the DunedinPACE clock) — small but the best controlled human data we have.
• Rapamycin, metformin, senolytics, NAD+ precursors, urolithin A, spermidine, and alpha-ketoglutarate show compelling animal data; in humans most are at the safety / early-signal stage, not the proven-to-extend-healthspan stage.
• GLP-1 receptor agonists (e.g., semaglutide) have unexpectedly become an aging-biology story, with large trials showing cardiovascular and mortality benefits beyond weight loss.
• Partial cellular reprogramming (Yamanaka factors) is the field's most exciting frontier — but it remains pre-clinical, with real safety questions, and is not a human therapy.
• "Aging clocks" let trials measure aging in months instead of decades, but the clocks themselves are still being validated and should be read cautiously.

What Is Human Longevity Science, and Why Does It Matter?

Longevity science (often called geroscience or biogerontology) is the study of the biological mechanisms of aging and whether they can be slowed, stopped, or reversed. The field's central idea — the geroscience hypothesis — is that aging itself is the largest shared risk factor for cancer, heart disease, dementia, type 2 diabetes, and most other chronic conditions. If you could slow the underlying aging process, you might delay all of these diseases simultaneously, rather than playing whack-a-mole one disease at a time [1, 2].

Crucially, the realistic goal is healthspan, not lifespan. Healthspan is the portion of life spent in good health, free of serious chronic disease and disability. Lifespan is total years lived. The most credible researchers in the field aim to compress the period of late-life illness — the "morbidity" — so that people stay healthy longer, not to make humans immortal. As geroscientists put it, the aim is to "die young as late as possible."

This distinction matters for reading the news. Headlines that promise to "reverse aging" or add decades to your life almost always overstate animal data or surrogate measurements. The honest version of the science is more incremental — and more interesting.

The Hallmarks of Aging: A Framework for Understanding the Field

In 2013, a landmark paper proposed nine hallmarks of aging — distinct, measurable biological processes that drive the aging phenotype. In January 2023, López-Otín, Blasco, Partridge, Serrano, and Kroemer updated the framework in Cell to twelve hallmarks [3]. This framework is the conceptual backbone of nearly every longevity intervention discussed below.

The 12 hallmarks of aging (2023) are:

1. Genomic instability — accumulating DNA damage and mutations
2. Telomere attrition — protective chromosome caps shortening with each cell division
3. Epigenetic alterations — drifting patterns of DNA methylation and gene expression
4. Loss of proteostasis — failure to maintain and clear proteins, leading to misfolded protein buildup
5. Disabled macroautophagy (new in 2023) — declining cellular "self-cleaning" recycling
6. Deregulated nutrient sensing — disrupted insulin/IGF-1, mTOR, AMPK, and sirtuin signaling
7. Mitochondrial dysfunction — the cell's power plants becoming less efficient
8. Cellular senescence — "zombie" cells that stop dividing but secrete inflammatory signals
9. Stem cell exhaustion — declining regenerative capacity
10. Altered intercellular communication — including immune and hormonal signaling
11. Chronic inflammation (new in 2023) — "inflammaging," low-grade persistent inflammation
12. Dysbiosis (new in 2023) — an altered, less healthy gut microbiome

To qualify as a hallmark, a process must meet three criteria: it appears with age; experimentally worsening it accelerates aging; and therapeutically improving it slows, stops, or reverses aging in a model organism [3]. The three new 2023 hallmarks — disabled macroautophagy, chronic inflammation, and dysbiosis — reflect how much the field has expanded in a decade.

Importantly, the hallmarks are interconnected, not independent. Senescent cells drive inflammation; mitochondrial decline feeds genomic instability; nutrient-sensing pathways like mTOR sit upstream of autophagy. This interconnection is why a single intervention (say, clearing senescent cells) can ripple across several hallmarks at once — and why aging is so hard to "fix" with one magic bullet.

The Major Intervention Classes: An Honest Evidence Scorecard

Below, each major class of longevity intervention is summarized with an honest evidence tier. The tiers are:

• Proven foundation — robust human outcome data over decades
• Robust human data — strong, replicated human trials for specific outcomes
• Early human trial — small or pilot human trials; safety/early signals only
• Pre-clinical — animal/cell data only; not yet meaningfully tested in humans

Summary Table: Longevity Interventions at a Glance

Senolytics: Clearing the "Zombie" Cells

Senescent cells are cells that have permanently stopped dividing but refuse to die, instead secreting a toxic cocktail of inflammatory molecules (the senescence-associated secretory phenotype, or SASP). They accumulate with age and drive the "inflammaging" hallmark. Senolytics are drugs that selectively kill these cells; senomorphics suppress their harmful secretions.

The flagship combination is dasatinib plus quercetin (D+Q) — a repurposed leukemia drug paired with a plant flavonoid. In a small first-in-human study of diabetic kidney disease, D+Q measurably reduced senescent cell burden in human tissue [5]. A phase I pilot in idiopathic pulmonary fibrosis (IPF) found the regimen feasible and generally tolerable, with hints of improved physical function [6]. A 2023 open-label phase I feasibility trial in mild Alzheimer's disease (the SToMP-AD study, Gonzales et al., Nature Medicine) showed dasatinib crossed into cerebrospinal fluid and the regimen was safe, though cognitive endpoints did not change in just five participants over 12 weeks [7]. Fisetin, a flavonoid found in strawberries, extended healthspan and lifespan in mice as a senotherapeutic [23] and is now in human trials, including in frailty and osteoarthritis.

Honest evidence tier: early human trial. Senolytics are one of the most exciting areas, but every human trial so far is small, short, and focused on safety or single diseases — not lifespan. The "hit-and-run" intermittent dosing concept is appealing but unproven for healthy aging.

Rapamycin and Rapalogs: Dialing Down mTOR

Rapamycin (sirolimus) is an FDA-approved immunosuppressant that inhibits mTOR, a master nutrient-sensing kinase. Inhibiting mTOR mimics aspects of caloric restriction, boosts autophagy, and is the single most reproducible way to extend lifespan across yeast, worms, flies, and mice — where it extends median lifespan even when started late in life.

In humans, the picture is earlier. The PEARL trial (Moel et al., Aging, 2025) — the largest and longest randomized trial of rapamycin for healthy aging to date — followed 114 adults aged 50–85 on low-dose intermittent rapamycin (5 or 10 mg/week) for 48 weeks. It found the regimen safe, with sex-specific improvements: women on 10 mg/week showed gains in lean tissue mass and reductions in pain [8]. Earlier work by Mannick and colleagues showed a rapamycin analog (rapalog) improved vaccine response in older adults, suggesting partial reversal of immune aging.

The Dog Aging Project's TRIAD trial is testing whether rapamycin extends lifespan and healthspan in companion dogs — a landmark because it is the first rigorous test of an anti-aging drug with lifespan endpoints in a large mammal outside the lab. The study design was published in GeroScience in 2025; the trial is still enrolling toward ~580 dogs, and definitive results are years away [9].

Honest evidence tier: early human trial. Rapamycin has the strongest animal lifespan data of any drug here, but human use for healthy aging is off-label, dosing is unsettled, and long-term safety in healthy people is unknown.

Metformin: The Cheap Drug Everyone Is Watching

Metformin is a first-line, decades-old type 2 diabetes drug that activates AMPK and influences several aging hallmarks. Some observational studies suggested diabetics on metformin live as long as or longer than non-diabetics — a striking but confounded finding.

The famous TAME trial (Targeting Aging with Metformin), championed by Nir Barzilai, is designed to test whether metformin delays the onset of multiple age-related diseases in older adults — and, just as importantly, to establish a regulatory precedent that "aging" can be a treatable indication. As of 2026, TAME remains only partially funded and has not fully launched, largely because metformin is generic and off-patent, giving pharmaceutical companies little incentive to fund it [10]. Meanwhile, some studies (notably in exercising adults) suggest metformin may blunt the benefits of exercise on muscle mitochondrial adaptation — a reminder that geroprotectors can have trade-offs.

Honest evidence tier: robust for diabetes; unproven for healthy-aging. The key human aging trial does not yet exist in completed form.

NAD+ Precursors (NMN and NR): Popular, but the Jury Is Out

NAD+ is a coenzyme central to energy metabolism and DNA repair that declines with age. The idea behind nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) is to restore NAD+ levels. Human trials confirm these supplements safely and reliably raise blood NAD+ [11]. The harder question is whether that translates to meaningful clinical benefit.

Results are mixed. A well-controlled study found NMN improved muscle insulin sensitivity in prediabetic women [12]. Other RCTs show modest or inconsistent effects on physical performance and metabolic markers [13]. No human trial has shown NMN or NR extends lifespan or reverses aging in any hard outcome. There is also a regulatory wrinkle: the U.S. FDA has taken the position that NMN is excluded from the dietary-supplement definition because it has been studied as a drug — adding commercial uncertainty.

Honest evidence tier: early human trial. Raising NAD+ is real; the downstream payoff for healthy aging is still unproven.

Mitophagy Activators: Urolithin A

Mitophagy is the cell's process of clearing out damaged mitochondria — and it declines with age. Urolithin A, a metabolite the gut microbiome makes from ellagitannins (found in pomegranates and walnuts), is a mitophagy activator. It extended lifespan in C. elegans and improved muscle function in rodents [24].

Unusually for this list, urolithin A has multiple completed human RCTs. It is safe and induces a molecular signature of improved mitochondrial health [14]; randomized trials in older and middle-aged adults show improvements in muscle endurance and strength [15, 16]. A 2024 systematic review concluded the human evidence for muscle and mitochondrial benefit is among the more solid in the nutraceutical longevity space, while cautioning that whole-organism "anti-aging" claims remain unproven [17]. A 2025 RCT also reported effects on age-related immune decline.

Honest evidence tier: robust human data for muscle/mitochondrial endpoints; not lifespan.

Alpha-Ketoglutarate (Ca-AKG)

Alpha-ketoglutarate (AKG) is a central metabolite in the Krebs cycle that also influences epigenetic enzymes and TOR signaling. In a notable 2020 study, calcium-AKG extended lifespan and, more strikingly, compressed morbidity (shortened the sick period) in aging mice [18]. AKG declines with age, and early human pilot data and reviews suggest it may reduce biological-age clock measurements, though these studies are small and often not placebo-controlled [19].

Honest evidence tier: pre-clinical to early human trial. The mouse morbidity-compression data are compelling; human evidence is thin and preliminary.

Spermidine and Other Caloric-Restriction Mimetics

Spermidine, a polyamine found in foods like wheat germ and aged cheese, induces autophagy and is a leading caloric-restriction mimetic [25, 26]. Observational data link higher dietary spermidine to lower mortality. The randomized SmartAge trial tested spermidine for cognition in older adults with subjective cognitive decline; the primary cognitive endpoint was not significantly improved, possibly due to dosing [20]. Other CR-mimetic candidates (e.g., resveratrol) have largely disappointed in rigorous human trials.

Honest evidence tier: early human trial; mixed.

GLP-1 Receptor Agonists: The Surprise Aging Story

Drugs like semaglutide and tirzepatide — originally diabetes and obesity treatments — have become an unexpected longevity-biology story. In the large SELECT trial (17,604 adults with cardiovascular disease and overweight/obesity but not diabetes), semaglutide reduced major adverse cardiovascular events by ~20%, with all-cause mortality trending lower [21]. Notably, much of the cardiovascular benefit appeared before significant weight loss, hinting at direct anti-inflammatory and metabolic effects relevant to aging biology. Emerging analyses also report associations with lower dementia and stroke risk, and one study reported a slowing of an epigenetic-aging measure on treatment.

Honest evidence tier: robust human data for cardiovascular/mortality endpoints in specific populations. Whether GLP-1 drugs are genuine "geroprotectors" for healthy people — versus excellent treatments for cardiometabolic disease — is an open and actively studied question.

Epigenetic / Partial Reprogramming: The Frontier

The most futuristic frontier is partial cellular reprogramming. The Yamanaka factors (Oct4, Sox2, Klf4, Myc — "OSKM") can convert adult cells back into stem-cell-like states. The longevity insight is that brief, partial expression appears to reset epigenetic age markers and restore youthful function in cells without erasing cell identity — directly targeting the "epigenetic alterations" hallmark.

In mice, cyclic partial reprogramming has reversed signs of aging in specific tissues, improved regeneration, and in some gene-therapy studies extended lifespan in aged animals [22]. Researchers increasingly favor the safer three-factor "OSK" combination (dropping the cancer-associated Myc) and cell-restricted, transient dosing. But the risks are real: too much reprogramming can cause loss of cell identity, tissue failure, or teratomas (tumors).

Honest evidence tier: pre-clinical. This is genuinely exciting laboratory science. It is not an available or proven human therapy, and anyone selling "reprogramming" treatments today is far ahead of the evidence.

How Do Scientists Even Measure "Aging" in a Trial?

A core problem: you cannot run a lifespan trial in humans in any reasonable timeframe. Waiting decades for participants to die is impractical, expensive, and ethically fraught. So researchers rely on surrogate endpoints — measurable proxies that, ideally, predict longevity.

Aging Clocks (Epigenetic Biomarkers)

Epigenetic clocks estimate "biological age" from DNA methylation patterns. First-generation clocks (Horvath, Hannum) estimate chronological age; second-generation clocks (PhenoAge, GrimAge) predict mortality and disease better; and DunedinPACE estimates the current rate of aging. These tools let a trial detect whether an intervention slows aging in months rather than decades.

The CALERIE caloric-restriction trial is the textbook example: it found CR slowed the DunedinPACE pace-of-aging clock by ~2–3% but did not significantly move PhenoAge or GrimAge [4]. That divergence is itself instructive — different clocks can disagree, and a small clock change of uncertain real-world meaning is easy to over-hype.

Caveats every reader should know: aging clocks are still being validated, can vary by tissue and measurement method, and a number that "improves" on a clock is not the same as proven added years of healthy life. Consumer "biological age" tests should be treated as interesting, not diagnostic.

Functional and Composite Measures

Trials also use grip strength, gait speed, VO2 max, frailty indices, immune-response markers, and inflammatory biomarkers (like IL-6 and CRP). These are closer to what people actually care about — staying strong and independent — and are often more meaningful than a single clock readout.

Why Is It So Hard to Prove a Longevity Drug Works in Humans?

Several structural challenges keep the field honest:

• Time and cost. A true lifespan trial is impractical; even healthspan trials need years and large samples to detect modest effects.
• Surrogate uncertainty. We are not yet certain which biomarker changes reliably translate into longer, healthier lives.
• No approval pathway for "aging." Regulators approve drugs for specific diseases, not for "aging" itself — part of why TAME matters as a precedent [10].
• Generic-drug economics. The most promising candidates (metformin, rapamycin) are off-patent, so there's little commercial incentive to fund definitive trials [10].
• Individual variation. Aging is heterogeneous; an intervention that helps one subgroup (e.g., women in PEARL) may not help another.
• Trade-offs. Geroprotectors can have downsides — immunosuppression (rapamycin), blunted exercise gains (metformin), or unknown long-term effects.

This is precisely why responsible scientists emphasize healthspan biomarkers and disease-delay endpoints rather than promising life extension.

Separating Hype From Evidence

The longevity field attracts genuine breakthroughs and genuine snake oil in equal measure. A few rules for reading any longevity claim:

1. "Reverses aging" almost always means a mouse or a cell line. Animal lifespan extension is real and important, but most interventions that work in mice fail or shrink dramatically in humans. Worms and flies are even further removed.
2. A biomarker is not an outcome. A drug nudging an epigenetic clock or raising NAD+ is a hypothesis-generating result, not proof you'll live longer or better.
3. Watch the dose and the population. PEARL found benefits mainly in women at the higher dose; effects rarely generalize cleanly.
4. Beware single small studies. Replication matters. Many headline "longevity" findings come from open-label pilots with a handful of participants.
5. Supplements ≠ approved drugs. NMN, fisetin, spermidine, urolithin A, and AKG are sold as supplements with variable quality and limited regulatory oversight. "Studied" does not mean "proven."
6. If someone sells you "reprogramming" or a guaranteed "biological age reversal," be skeptical. The science is real; the clinic-ready product is not.
7. The boring stuff has the best evidence. No supplement on the market matches the human outcome data for exercise, sleep, and not smoking.

What Should You Actually Do? The Evidence-Based Foundations

Stripped of hype, the interventions with the strongest human evidence for a longer, healthier life are remarkably ordinary — and free or cheap. These are educational summaries of what the research supports, not personalized medical advice.

• Move regularly. Both aerobic exercise and resistance/strength training have the deepest human evidence of anything in this article. Exercise hits multiple aging hallmarks (mitochondrial health, proteostasis, inflammation, glucose control) at once. Preserving muscle mass and strength is one of the best-supported predictors of healthy aging.
• Prioritize sleep. Chronic short or poor sleep is linked to inflammation, metabolic dysfunction, and cognitive decline. Sleep is when much cellular repair and autophagy occur.
• Don't smoke; limit alcohol. Smoking is the single most powerful accelerator of biological aging that's under your control. The mortality benefit of cessation rivals or exceeds anything pharmaceutical.
• Eat a whole-food, mostly plant-forward diet, and don't overeat. The CALERIE trial suggests modest caloric restriction can nudge biological aging measures [4]; dietary patterns rich in fiber, polyphenols, and unsaturated fats support the gut microbiome and reduce inflammation. You don't need an exotic protocol — quality and not chronically overeating matter most.
• Maintain metabolic and cardiovascular health. Keeping blood pressure, blood glucose, lipids, and waist circumference in healthy ranges prevents the diseases that aging accelerates. Much of "longevity medicine" is just rigorous prevention.
• Stay socially and cognitively engaged. Social connection and purpose are consistently associated with longevity in population studies.
• Be a cautious, informed consumer of supplements and off-label drugs. If you're considering rapamycin, metformin, senolytics, or NAD+ precursors, do it with a physician, with eyes open about the limited evidence, and never as a substitute for the foundations above.

The unglamorous truth of 2026: the proven path to a longer healthspan is mostly behavioral, and the pharmaceutical frontier — while genuinely promising — is still being built and tested.

Frequently Asked Questions

Can we reverse aging? Not in humans, not yet — not in any proven, durable sense. In the laboratory, partial cellular reprogramming and senescent-cell clearance can reverse specific aging markers in animals and cells. In people, some interventions modestly slow measures of biological aging, but reversing human aging as a whole remains an unproven, frontier goal.

Does metformin extend lifespan in humans? There's no completed randomized trial proving it does. Observational data are suggestive but confounded. The TAME trial is designed to test metformin's ability to delay age-related diseases, but as of 2026 it remains only partially funded and has not fully launched [10].

What is the most proven way to live longer? Behavioral foundations: regular exercise (aerobic plus strength), good sleep, not smoking, moderate alcohol, and a whole-food diet without chronic overeating. These have far stronger human outcome data than any supplement or longevity drug.

Are aging clocks accurate? They're useful research tools but imperfect. Different clocks can disagree (CALERIE moved DunedinPACE but not GrimAge), they vary by tissue and method, and a "better" clock reading isn't proof of added healthy years [4]. Treat consumer biological-age tests as interesting, not diagnostic.

Is rapamycin safe to take for anti-aging? Rapamycin has the strongest animal lifespan data of any drug, and the PEARL human trial found low-dose intermittent use generally safe over a year, with some benefits in women [8]. But it's used off-label for aging, optimal dosing is unsettled, long-term safety in healthy people is unknown, and it can suppress immune function. This is a medical decision, not a supplement choice.

Do NMN and NR supplements work? They reliably raise NAD+ levels and appear safe in trials [11], and NMN improved insulin sensitivity in one study [12]. But no human trial shows they extend lifespan or meaningfully reverse aging, and results on performance are mixed [13]. The evidence does not yet match the marketing.

Are GLP-1 drugs like Ozempic anti-aging drugs? They have strong human data for reducing cardiovascular events and mortality in specific high-risk groups, partly independent of weight loss [21]. Whether they're true "geroprotectors" for healthy people — versus excellent cardiometabolic-disease treatments — is an open scientific question, not a settled fact.

Does caloric restriction or fasting extend human lifespan? No human lifespan trial exists. The best controlled data, from CALERIE, show ~25% caloric restriction modestly slowed one pace-of-aging clock and improved metabolic and inflammatory markers over two years [4]. Benefits for human longevity are plausible but not proven, and severe restriction carries risks (muscle and bone loss).

What about senolytics — should I take dasatinib and quercetin or fisetin? Senolytics are a leading frontier, but every human trial so far is small and disease-specific (IPF, Alzheimer's, kidney disease), focused on safety [5–7]. Dasatinib is a prescription chemotherapy drug with real side effects. Fisetin trials are ongoing. None is proven for healthy-aging use.

Is partial reprogramming available as a treatment? No. Yamanaka-factor partial reprogramming is exciting pre-clinical science with promising mouse data but unresolved safety risks, including cancer [22]. There is no proven, approved human reprogramming therapy in 2026.

References

1. Kennedy BK, Berger SL, Brunet A, et al. Geroscience: linking aging to chronic disease. Cell. 2014;159(4):709-713. doi:10.1016/j.cell.2014.10.039. https://pubmed.ncbi.nlm.nih.gov/25417146/
2. Partridge L, Fuentealba M, Kennedy BK. The quest to slow ageing through drug discovery. Nature Reviews Drug Discovery. 2020;19(8):513-532. PMID: 32467649. doi:10.1038/s41573-020-0067-7. https://pubmed.ncbi.nlm.nih.gov/32467649/
3. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186(2):243-278. PMID: 36599349. doi:10.1016/j.cell.2022.11.001. https://pubmed.ncbi.nlm.nih.gov/36599349/
4. Waziry R, Ryan CP, Corcoran DL, et al. Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial. Nature Aging. 2023;3(3):248-257. PMID: 37118425. doi:10.1038/s43587-022-00357-y. https://pubmed.ncbi.nlm.nih.gov/37118425/
5. Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019;47:446-456. PMID: 31542391. doi:10.1016/j.ebiom.2019.08.069. https://pubmed.ncbi.nlm.nih.gov/31542391/
6. Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine. 2019;40:554-563. PMID: 30616998. doi:10.1016/j.ebiom.2018.12.052. https://pubmed.ncbi.nlm.nih.gov/30616998/
7. Gonzales MM, Garbarino VR, Kautz TF, et al. Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial. Nature Medicine. 2023;29(10):2481-2488. PMID: 37679434. doi:10.1038/s41591-023-02543-w. https://pubmed.ncbi.nlm.nih.gov/37679434/
8. Moel M, Harinath G, Lee V, Nyquist A, Morgan SL, Isman A, Zalzala S. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging (Albany NY). 2025;17(4):908-936. PMID: 40188830. doi:10.18632/aging.206235. https://pubmed.ncbi.nlm.nih.gov/40188830/
9. Creevy KE, Akey JM, Kaeberlein M, Promislow DEL; Dog Aging Project Consortium. Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale. GeroScience. 2025. doi:10.1007/s11357-024-01484-7. https://link.springer.com/article/10.1007/s11357-024-01484-7
10. Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a Tool to Target Aging. Cell Metabolism. 2016;23(6):1060-1065. PMID: 27304507. doi:10.1016/j.cmet.2016.05.011. https://pubmed.ncbi.nlm.nih.gov/27304507/ (TAME trial overview: American Federation for Aging Research, https://www.afar.org/tame-trial)
11. Yi L, Maier AB, Tao R, et al. The efficacy and safety of ?-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023;45(1):29-43. PMID: 36482258. doi:10.1007/s11357-022-00705-1. https://pubmed.ncbi.nlm.nih.gov/36482258/
12. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PMID: 33888596. doi:10.1126/science.abe9985. https://pubmed.ncbi.nlm.nih.gov/33888596/
13. Guarente L, Sinclair DA, Kroemer G. Human trials exploring anti-aging medicines. Cell Metabolism. 2024;36(2):354-376. PMID: 38181790. doi:10.1016/j.cmet.2023.12.007. https://pubmed.ncbi.nlm.nih.gov/38181790/
14. Andreux PA, Blanco-Bose W, Ryu D, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Metabolism. 2019;1(6):595-603. PMID: 32694802. doi:10.1038/s42255-019-0073-4. https://pubmed.ncbi.nlm.nih.gov/32694802/
15. Liu S, D'Amico D, Shankland E, et al. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA Network Open. 2022;5(1):e2144279. PMID: 35050355. doi:10.1001/jamanetworkopen.2021.44279. https://pubmed.ncbi.nlm.nih.gov/35050355/
16. Singh A, D'Amico D, Andreux PA, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Reports Medicine. 2022;3(5):100633. PMID: 35584623. doi:10.1016/j.xcrm.2022.100633. https://pubmed.ncbi.nlm.nih.gov/35584623/
17. Kuerec AH, Lim XK, Khoo AL, et al. Targeting aging with urolithin A in humans: A systematic review. Ageing Research Reviews. 2024;100:102406. PMID: 39002645. doi:10.1016/j.arr.2024.102406. https://pubmed.ncbi.nlm.nih.gov/39002645/
18. Asadi Shahmirzadi A, Edgar D, Liao CY, et al. Alpha-Ketoglutarate, an Endogenous Metabolite, Extends Lifespan and Compresses Morbidity in Aging Mice. Cell Metabolism. 2020;32(3):447-456.e6. PMID: 32877690. doi:10.1016/j.cmet.2020.08.004. https://pubmed.ncbi.nlm.nih.gov/32877690/
19. Gyanwali B, Lim ZX, Soh J, et al. Alpha-Ketoglutarate dietary supplementation to improve health in humans. Trends in Endocrinology and Metabolism. 2022;33(2):136-146. PMID: 34952764. doi:10.1016/j.tem.2021.11.003. https://pubmed.ncbi.nlm.nih.gov/34952764/
20. Schwarz C, Benson GS, Horn N, et al. Effects of Spermidine Supplementation on Cognition and Biomarkers in Older Adults With Subjective Cognitive Decline: A Randomized Clinical Trial. JAMA Network Open. 2022;5(5):e2213875. PMID: 35616942. doi:10.1001/jamanetworkopen.2022.13875. https://pubmed.ncbi.nlm.nih.gov/35594047/
21. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023;389(24):2221-2232. PMID: 37952131. doi:10.1056/NEJMoa2307563. https://pubmed.ncbi.nlm.nih.gov/37952131/
22. Browder KC, Reddy P, Yamamoto M, et al. In vivo partial reprogramming alters age-associated molecular changes during physiological aging in mice. Nature Aging. 2022;2(3):243-253. PMID: 37118377. doi:10.1038/s43587-022-00183-2. https://pubmed.ncbi.nlm.nih.gov/37118377/
23. Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28. PMID: 30279143. doi:10.1016/j.ebiom.2018.09.015. https://pubmed.ncbi.nlm.nih.gov/30279143/
24. Ryu D, Mouchiroud L, Andreux PA, et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nature Medicine. 2016;22(8):879-888. PMID: 27400265. doi:10.1038/nm.4132. https://pubmed.ncbi.nlm.nih.gov/27400265/
25. Madeo F, Eisenberg T, Pietrocola F, Kroemer G. Spermidine in health and disease. Science. 2018;359(6374):eaan2788. PMID: 29371440. doi:10.1126/science.aan2788. https://pubmed.ncbi.nlm.nih.gov/29371440/
26. Madeo F, Carmona-Gutierrez D, Hofer SJ, Kroemer G. Caloric Restriction Mimetics against Age-Associated Disease: Targets, Mechanisms, and Therapeutic Potential. Cell Metabolism. 2019;29(3):592-610. PMID: 30840912. doi:10.1016/j.cmet.2019.01.018. https://pubmed.ncbi.nlm.nih.gov/30840912/
27. Kroemer G, Maier AB, Cuervo AM, Gladyshev VN, Ferrucci L, Gorbunova V, et al. From geroscience to precision geromedicine: Understanding and managing aging. Cell. 2025;188(8):2043-2062. PMID: 40250404. doi:10.1016/j.cell.2025.03.011. https://pubmed.ncbi.nlm.nih.gov/40250404/

Educational Disclaimer

This article is for educational and informational purposes only and does not constitute medical advice. It is a summary of published scientific research and does not endorse any product, supplement, drug, or treatment. Longevity drugs and supplements discussed here (including rapamycin, metformin, senolytics, NAD+ precursors, and others) carry risks and may interact with medications or health conditions. Always consult a qualified physician or healthcare professional before starting, stopping, or changing any supplement, medication, diet, or exercise regimen. Statements about supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.

Several of the better-studied compounds discussed here — including urolithin A, calcium alpha-ketoglutarate, and taurine — are the basis of Ares, SciRouter's human longevity formula. As the research above stresses, supplements sit on top of the proven foundations, never in place of them.

Related reading: 6 Longevity Molecules With Real Science Behind Them.

Published by the SciRouter Editorial Team for general educational purposes. Last updated June 2026. SciRouter is an educational science publisher and computational-science platform.